DARA Biosciences's gross profit for the
three
months ended in Sep. 2015 was $0.94 Mil. DARA Biosciences's gross profit for the trailing twelve months (TTM) ended in Sep. 2015 was $2.72 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. DARA Biosciences's gross profit for the
three
months ended in Sep. 2015 was $0.94 Mil. DARA Biosciences's Revenue for the
three
months ended in Sep. 2015 was $1.18 Mil. Therefore, DARA Biosciences's Gross Margin % for the quarter that ended in Sep. 2015 was 79.59%.
DARA Biosciences had a gross margin of 79.59% for the quarter that ended in Sep. 2015 => Durable competitive advantage
DARA Biosciences Gross Profit Historical Data
The historical data trend for DARA Biosciences's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DARA Biosciences's Gross Profit
For the Biotechnology subindustry, DARA Biosciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DARA Biosciences's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DARA Biosciences's Gross Profit distribution charts can be found below:
* The bar in red indicates where DARA Biosciences's Gross Profit falls into.
DARA Biosciences Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
DARA Biosciences's Gross Profit for the fiscal year that ended in Dec. 2014 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.72 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
DARA Biosciences (NAS:DARA) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
DARA Biosciences had a gross margin of 79.59% for the quarter that ended in Sep. 2015 => Durable competitive advantage
DARA Biosciences Gross Profit Related Terms
Thank you for viewing the detailed overview of DARA Biosciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
DARA Biosciences (DARA Biosciences) Business Description
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DARA has been successfully added to your 